Advertisement

Der Internist

, Volume 60, Issue 2, pp 209–216 | Cite as

Stellenwert von Acetylsalicylsäure in der Primärprävention

ASCEND, ARRIVE and ASPREE as well as a meta-analysis by Rothwell et al.
  • K. SchrörEmail author
  • S. Nitschmann
Klinische Studien
  • 140 Downloads

Originalliteratur

The ASCEND Study Collaborative Group (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 379:1529–1539

Gaziano JM, Brotons C, Coppolecchia R et al (2018) Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392:1036–1046

McNeil JJ, Wood RL, Nelson MR et al for the ASPREE Investigator-Group (2018) Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med  https://doi.org/10.1056/NEJMoa1800722

McNeil JJ, Nelson MR, Wood RL et al for the ASPREE Investigator-Group (2018) Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med  https://doi.org/10.1056/NEJMoa1803955

McNeil JJ, Wolfe R, Wood RL et al for the ASPREE Investigator-Group (2018) Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med  https://doi.org/10.1056/NEJMoa1805819...

Importance of acetylsalicylic acid in primary prevention

ASCEND, ARRIVE and ASPREE as well as a meta-analysis by Rothwell et al.

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

K. Schrör und S. Nitschmann geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849–1860CrossRefGoogle Scholar
  2. 2.
    Belch J, MacCuish A et al (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840CrossRefGoogle Scholar
  3. 3.
    Bhatt DL, Grosser T et al (2017) Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. J Am Coll Cardiol 69(6):603–612CrossRefGoogle Scholar
  4. 4.
    Chamberlain JJ, Johnson EL et al (2018) Cardiovascular disease and risk management: review of the American Diabetes Association standards of medical care in diabetes 2018. Ann Intern Med 168(9):640–650CrossRefGoogle Scholar
  5. 5.
    Chapman MJ (2007) From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. Pharmacol Ther 113(1):184–196CrossRefGoogle Scholar
  6. 6.
    Cuzick J, Thorat MA et al (2015) Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26(1):47–57CrossRefGoogle Scholar
  7. 7.
    Faulkner M, Alikhaani J et al (2018) Exploring meaningful patient engagement in ADAPTABLE (Aspirin dosing: a patient-centric trial assessing benefits and long-term effectiveness). Med Care 56(10 Suppl 1):S11–S15CrossRefGoogle Scholar
  8. 8.
    Haffner SM, Lehto S et al (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229–234CrossRefGoogle Scholar
  9. 9.
    Kwok CS, Shoamanesh A et al (2015) Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. Stroke 46(4):1014–1023CrossRefGoogle Scholar
  10. 10.
    McNeil JJ, Wolfe R et al (2018) Effect of Aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med.  https://doi.org/10.1016/50140-6736(18)31924-X CrossRefPubMedGoogle Scholar
  11. 11.
    Millard MA, Hernandez-Vila EA (2018) What do the guidelines really say about Aspirin. Tex Heart Inst J 45(4):228–230CrossRefGoogle Scholar
  12. 12.
    Patrono C, Garcia Rodriguez LA et al (2005) Low-dose Aspirin for the prevention of atherothrombosis. N Engl J Med 353(22):2373–2383CrossRefGoogle Scholar
  13. 13.
    Rothwell PM, Algra A et al (2016) Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 388(10042):365–375CrossRefGoogle Scholar
  14. 14.
    Rothwell PM, Fowkes FG et al (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31–41CrossRefGoogle Scholar
  15. 15.
    Rothwell PM, Price JF et al (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379(9826):1602–1612CrossRefGoogle Scholar
  16. 16.
    Schrör K (2018) Acetylsalicylsäure. Dr. Schrör Verlag, FrechenGoogle Scholar
  17. 17.
    Schrör K, Huber K et al (2011) Functional testing methods for the antiplatelet effects of Aspirin. Biomark Med 5(1):31–42CrossRefGoogle Scholar
  18. 18.
    Schrör K, Hohlfeld T (2015) NSAID beim Herzpatienten – Probleme und Alternativen. Herzmedizin 01/2015:33–38Google Scholar
  19. 19.
    Sexton T et al (2016) Anti-thrombotic effects of statins in acute coronary syndromes: at the intersection of thrombosis, inflammation, and platelet-leukocyte interactions. Curr Cardiol Rev 72:324–329CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Institut für Pharmakologie und Klinische PharmakologieUniversitätsklinikum DüsseldorfDüsseldorfDeutschland
  2. 2.LippetalDeutschland

Personalised recommendations